id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-N-6313-0002,FDA,FDA-2017-N-6313,Prescription Drug User Fee Act VI Commitment to Assess Current Practices of the Food and Drug Administration and Sponsors in Communicating During Investigational New Drug Development; Establishment of a Public Docket; Request for Comments,Other,Assessment Document or Analysis,2017-12-08T05:00:00Z,2017,12,2017-12-08T05:00:00Z,,2018-01-24T17:30:42Z,,0,0,0900006482cf38d4
FDA-2017-N-6313-0001,FDA,FDA-2017-N-6313,"Prescription Drug User Fee Act VI Commitment To Assess Current  Practices of the Food and Drug Administration and Sponsors in
Communicating During Investigational New Drug Development; Establishment of a Public Docket; Request for Comments",Notice,Request for Comments,2017-12-08T05:00:00Z,2017,12,2017-12-08T05:00:00Z,2018-01-23T04:59:59Z,2018-01-23T02:02:52Z,2017-26437,0,0,0900006482cf28d9